CINECA IRIS Institutional Research Information System

CIAMPI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.905
EU - Europa 4.819
AS - Asia 3.632
SA - Sud America 477
Continente sconosciuto - Info sul continente non disponibili 227
AF - Africa 203
OC - Oceania 7
Totale 17.270
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.670
IT - Italia 2.001
CN - Cina 1.054
SG - Singapore 1.047
DE - Germania 883
HK - Hong Kong 648
SE - Svezia 614
BR - Brasile 398
VN - Vietnam 303
GB - Regno Unito 256
BG - Bulgaria 206
AT - Austria 170
CA - Canada 165
FR - Francia 147
TR - Turchia 133
FI - Finlandia 128
RU - Federazione Russa 128
IN - India 117
CI - Costa d'Avorio 104
JP - Giappone 74
NL - Olanda 71
UA - Ucraina 61
KR - Corea 50
SN - Senegal 44
BD - Bangladesh 39
IQ - Iraq 27
MX - Messico 26
PL - Polonia 25
CH - Svizzera 22
AR - Argentina 20
ZA - Sudafrica 20
BE - Belgio 18
SA - Arabia Saudita 17
EC - Ecuador 16
EE - Estonia 15
PK - Pakistan 15
VE - Venezuela 15
ES - Italia 14
ID - Indonesia 14
MA - Marocco 12
UZ - Uzbekistan 12
TW - Taiwan 10
CO - Colombia 9
JM - Giamaica 9
CZ - Repubblica Ceca 8
IL - Israele 8
IR - Iran 8
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 7
CR - Costa Rica 7
GT - Guatemala 7
KE - Kenya 7
PH - Filippine 7
HU - Ungheria 6
JO - Giordania 6
RO - Romania 6
GR - Grecia 5
LT - Lituania 5
MY - Malesia 5
PS - Palestinian Territory 5
PY - Paraguay 5
UY - Uruguay 5
AL - Albania 4
AU - Australia 4
BY - Bielorussia 4
CL - Cile 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
HN - Honduras 4
IE - Irlanda 4
PA - Panama 4
PE - Perù 4
RS - Serbia 4
EU - Europa 3
NG - Nigeria 3
NI - Nicaragua 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
TH - Thailandia 3
DK - Danimarca 2
EG - Egitto 2
LK - Sri Lanka 2
MK - Macedonia 2
OM - Oman 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BO - Bolivia 1
BS - Bahamas 1
BZ - Belize 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
Totale 17.033
Salva come PNG Salva come JPEG
Città #
Ashburn 884
Dallas 660
Hong Kong 632
Woodbridge 593
Singapore 580
Fairfield 464
San Jose 458
Ann Arbor 393
Chandler 391
Santa Clara 391
Houston 349
Milan 314
Beijing 221
Shanghai 210
Sofia 204
New York 181
Seattle 173
Wilmington 166
Vienna 162
Cambridge 151
Los Angeles 122
Council Bluffs 113
Ottawa 111
Abidjan 104
Boardman 104
Pisa 99
Rome 99
Princeton 91
Ho Chi Minh City 84
Florence 83
Lawrence 75
Lauterbourg 70
Munich 69
Medford 64
Frankfurt am Main 63
Serra 63
Izmir 62
Tokyo 60
Jacksonville 59
Hanoi 55
Hefei 55
Dearborn 54
Helsinki 52
Nanjing 52
London 51
São Paulo 51
Naples 47
Des Moines 46
Seoul 45
Dakar 44
Istanbul 44
Redondo Beach 43
Buffalo 42
Bologna 35
Bremen 35
San Diego 34
Orem 31
Düsseldorf 25
Dong Ket 24
Tianjin 24
Chicago 21
Redmond 21
Redwood City 21
Boulder 20
Columbus 20
Lancaster 20
Nanchang 20
Turin 19
Atlanta 17
Cascina 17
Fuzhou 17
Brussels 16
Genoa 16
Verona 16
Baghdad 15
Bern 15
Brooklyn 15
Guangzhou 15
Ogden 15
Palermo 15
Rio de Janeiro 15
Toronto 15
Turku 15
Washington 15
Bengaluru 14
Boston 14
Hangzhou 14
Montreal 14
Parma 13
Belo Horizonte 12
Changsha 12
Johannesburg 12
Phoenix 12
Tashkent 12
Jaboatão 11
Jüchen 11
Poplar 11
San Francisco 11
Trieste 11
Warsaw 11
Totale 10.667
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.179
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 355
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 296
LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER. 282
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 262
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 249
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 248
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 240
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 231
Targeted Therapy in Thyroid Cancer: State of the Art 231
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 231
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 230
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 230
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 227
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 220
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 216
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 214
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 210
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 207
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 204
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 203
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 203
BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer 200
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 200
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer 194
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 194
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 193
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 189
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 187
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 186
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 185
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 181
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 181
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 181
Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors 180
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 177
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 171
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 170
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 168
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 166
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 164
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 163
BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization 161
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 160
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 160
null 160
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 158
null 157
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients 155
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 155
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 153
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 153
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 149
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 148
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 148
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RAR{beta} mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 147
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 147
null 146
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 145
Alterations of the BRAF gene in thyroid tumors 145
WHOLE EXOME SEQUENCING OF MEDULLARY THYROID CARCINOMA CASES IDENTIFIES 86 VARIATIONS IN GENES POSSIBLY INVOLVED IN TUMORAL TRANSFORMATION 144
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance 138
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 138
Ret mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 138
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 137
Studi in vitro del trattamento con acido retinoico di linee cellulari di carcinoma tiroideo umano anaplastico, scarsamente differenziato, follicolare e midollare 136
Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid 135
Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience 132
All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes 132
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature 131
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation 130
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 129
The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma 128
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas 128
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 128
HOOK3-RET: A novel type of RET/PTC rearrangement in papillary thyroid carcinoma 125
Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis 124
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer 121
Genetic heterogeneity of Medullary Thyroid Carcinoma 121
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma 120
NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas 117
Whole Exome Sequencing of Medullary Thyroid Carcinomas did not identify oncogenic drivers alternative to RET and RAS genes 115
Minireview: RET/PTC rearrangements and braf mutations in thyroid tumorigenesis 111
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: Effects of the detection methods and genetic heterogeneity 110
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation: A model of carcinogenic chromosomal rearrangement induced by ionizing radiation 107
Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients 106
The prognostic role of chromosomal gains and loss in sporadic medullary thyroid carcinoma 106
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 102
BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review 99
null 99
MULTIFOCALITY AND BILATERALITY IN MEDULLARY THYROID CANCER: BASIS FOR A PROOF-OF-CONCEPT SAFETY OF LOBECTOMY 98
SIMULTANEOUS MEDULLARY AND PAPILLARY THYROID CARCINOMAS SHOW INDEPENDENT GENETIC ORIGIN 98
Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value 97
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs 96
Ret Oncogene and Thyroid Carcinoma 89
BRAF(V600E) mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC) 87
null 75
null 70
Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib 67
null 58
Totale 17.067
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.606
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.606
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022972 0 0 21 75 211 131 36 47 55 49 78 269
2022/20231.735 205 247 139 136 143 187 61 124 310 37 107 39
2023/20241.384 158 130 126 109 167 201 117 79 63 39 67 128
2024/20253.260 65 139 63 185 341 294 267 205 328 402 368 603
2025/20264.139 266 589 521 356 399 286 640 200 250 365 141 126
2026/2027742 81 331 330 0 0 0 0 0 0 0 0 0
Totale 17.270